ARCUTIS BIOTHERAPEUTICS, INC. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings of $139.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings · last filed 2026-02-25
- ARCUTIS BIOTHERAPEUTICS, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2025-12-31 was -$71.00K.
- ARCUTIS BIOTHERAPEUTICS, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2025-09-30 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for the quarter ending 2025-03-31 was $210.00K, a 61.33% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for fiscal 2025 was $139.00K, a 50.18% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for fiscal 2024 was $279.00K.
- ARCUTIS BIOTHERAPEUTICS, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, gain (loss) included in earnings for fiscal 2023 was -$849.00K.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 9 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$71.00K derived: sum of 2 quarters · filed 2026-02-25 | -$71.00K derived: sum of 3 quarters · filed 2026-02-25 | $139.00K 10-K · filed 2026-02-25 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $0.00 derived: sum of 2 quarters · filed 2025-10-28 | $210.00K 10-Q · filed 2025-10-28 | $60.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $210.00K 10-Q · filed 2025-08-06 | $60.00K derived: sum of 3 quarters · filed 2026-02-25 | -$166.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-03-31 | $210.00K 10-Q · filed 2025-05-06 | $60.00K derived: sum of 2 quarters · filed 2026-02-25 | -$166.00K derived: sum of 3 quarters · filed 2026-02-25 | -$54.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-12-31 | -$150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$376.00K derived: sum of 2 quarters · filed 2026-02-25 | -$264.00K derived: sum of 3 quarters · filed 2026-02-25 | $279.00K 10-K · filed 2026-02-25 |
| 2024-09-30 | -$226.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$114.00K derived: sum of 2 quarters · filed 2025-10-28 | $429.00K 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $112.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $655.00K 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $543.00K 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | -$849.00K 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |